MedTrace Logo

Blocking of the Gut Hormone Receptor for Glucagon-like Peptide 2 (GLP-2) by the GLP-2 Receptor Antagonist GLP-2(3-33)

NCT06774807 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2025-05-02

No results posted yet for this study

Summary

This project will describe the role of physiological levels of GLP-2 in regulating the blood flow to the intestines and the effect of the antagonist GLP-2(3-33) in blocking these effects of GLP-2.

Conditions

  • Healthy

Interventions

OTHER

Saline infusion

Saline/NaCl (9mg/ml) intravenous infusion

OTHER

Saline injection

Saline/NaCl (9mg/ml) subcutaneous injection

OTHER

1nmol antagonist infusion

GLP-2 (1-33)/GLP-2(3-33) 1 nmol/kg/min

OTHER

4 nmol antagonist infusion

GLP-2 (1-33)/GLP-2 (3-33) 4 nmol/kg/min

OTHER

Agonist injection

GLP-2(1-33) subcutaneous injection

Sponsors & Collaborators

  • Rigshospitalet, Denmark

    collaborator OTHER

  • University of Copenhagen

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-05-01
Primary Completion
2024-09-01
Completion
2024-09-07

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06774807 on ClinicalTrials.gov